Reading-headquartered medical products and technology company ConvaTec has added to its board with a new non-executive director appointment.
Dr Ros Rivaz has taken up her new position as a non-executive director of the company with immediate effect.
Her non-executive board experience spans FTSE 100, large private and not-for-profit organisations. Rivaz served as a non-executive director and chairman of the remuneration committee at Rexam prior to its acquisition by Ball Corporation in 2016, and currently sits on the board of RPC Group, Computacenter, Ministry of Defence Equipment and Support and is also vice chair of the council of Southampton University, among other roles.
Previously, Rivaz held a range of senior executive management roles across major FTSE100 and international businesses. From 2011 to 2014 she was global chief operating officer of Smith & Nephew, having previously served in senior operations, manufacturing and supply chain roles at Premier Foods, Diageo, ICI and Tate & Lyle.
Sir Christopher Gent, chairman of ConvaTec, said: “I am delighted to welcome Ros to the Board of ConvaTec. She brings exceptional and significant experience gained from a successful career across a variety of industries.
“Ros has a detailed understanding of the medical products and technology sector, and she will make a valuable contribution to ConvaTec. The board looks forward to working closely with her.”
Earlier this month, Nordic Capital and Avista agreed to sell 250 million shares in ConvaTec to institutional investors at a price of 322p per share, raising gross proceeds of £805m, through an accelerated bookbuilding process.
By Muhammad Aldalou
Source: Insider Media
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
